Drugs / NTF001
NTF001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07618585 | Apr 2026 → Mar 2028 expected | amyotrophic lateral sclerosis | Ruijin Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NTF001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07618585 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “AAV-mediated gene therapy product” NCT07618585 ↗ |
| Route | Intrathecal | “administered once by intrathecal injection” NCT07618585 ↗ |
| Target | NDNF | “designed to express human neuron-derived neurotrophic factor (NDNF)” NCT07618585 ↗ |